Protein / target
Growth hormone receptor
Protein at a glance
Biological role
Protein tyrosine kinase activator activity
Primary system
Endocrine & metabolic
Strongest disease association
Laron syndrome
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
6 approved
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Receptor for pituitary gland growth hormone (GH1) involved in regulating postnatal body growth (PubMed:1549776, PubMed:2825030, PubMed:8943276). On ligand binding, couples to the JAK2/STAT5 pathway (PubMed:1549776, PubMed:15690087, PubMed:2825030, PubMed:8943276)
Subcellular location
Domains and Gene Ontology detail (48)Hide
Domains & features
Gene Ontology
- Ccell surface
- Ccytosol
- Cexternal side of plasma membrane
- Cextracellular region
- Cextracellular space
- Cgrowth hormone receptor complex
- Cmembrane
- Cneuronal cell body
- Cplasma membrane
- Creceptor complex
- Fcytokine binding
- Fgrowth factor binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·cytokine binding
- ·cytokine-mediated signaling pathway
- ·response to interleukin-1
Metabolic enzyme activity
- ·hormone metabolic process
- ·taurine metabolic process
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Growth hormone receptor agonist
Growth hormone receptor agonist
Appears in clinical studies involving pituitary dwarfism, Growth delay, Turner syndrome, Noonan syndrome
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 1,358 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 6 total
acromegaly · McCune-Albright syndrome · acromegaly
pituitary dwarfism · Growth delay · Turner syndrome
Growth delay · pituitary dwarfism · pituitary dwarfism
pituitary dwarfism · pituitary dwarfism · Short stature
chronic kidney disease · Turner syndrome · pituitary dwarfism
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Related literature
Papers indexed under “Receptors, Somatotropin” — a subject heading that covers this protein without being specific to it. Shown as context; not counted as this protein's own research activity.
Europe PMC literature, reached through a MeSH descriptor linked to this protein.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- New publicationGrowth hormone treatment for neurologic symptoms of post-acute sequelae of COVID-19.
- New publicationComplex relationship between growth hormone and sleep in children: insights, discrepancies, and implications.
- New publicationRecent insights into the role of hormones during development and their functional regulation.
- New publicationA Superlong-Acting Growth Hormone-Polypeptide Fusion for Growth Hormone Deficiency Treatment.
- New publicationProlactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.
- New publicationInvestigation of the metabolic and endocrinological differences between daily and weekly growth hormone replacement therapy, somapacitan, in patients with adult growth hormone deficiency: A real-world pilot study.
- New publicationGrowth Hormone Action in Somatostatin Neurons Regulates Anxiety and Fear Memory.
- New publicationCancer in growth hormone excess and growth hormone deficit.
- New publicationAging under endocrine hormone regulation.
- New publicationComponents of the metabolic syndrome in girls with Turner syndrome treated with growth hormone in a long term prospective study.
- New publicationGrowth hormone remodels the 3D-structure of the mitochondria of inflammatory macrophages and promotes metabolic reprogramming.
- Regulatory approval
Approval: Sogroya (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.